You are here:
Hereditary transthyretin-mediated amyloidosis.
No estimate possible yet
Registration application pending
Vutrisiran
Neurological disorders
New medicine (specialité)
Neurological disorders other
Alnylam
Subcutaneous
Injection
Intermural (MSZ)
Systemically delivered RNA interference therapy.
Centralised (EMA)
Normal trajectory
No
September 2021
October 2022
Yes
There is currently nothing known about the expected patient volume.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines